SPI Pharma, Inc. a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of innate immune modulators, announce an agreement in principle to create a strategic collaboration to develop and commercialize advanced adjuvant systems for vaccine development. This collaboration leverages Inimmune’s world-class expertise in adjuvant formulation and immunotherapeutics and SPI Pharma’s extensive manufacturing and global commercial capabilities.
